Does septal thickness influence outcome of myectomy for hypertrophic obstructive cardiomyopathy?

Anita Nguyen1, Hartzell V Schaff1, Rick A Nishimura2

  • 1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA.

Insights

Transaortic septal myectomy effectively relieves left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy patients, even with basal septal thickness <18 mm. Mitral valve procedures are typically unnecessary unless intrinsic disease or residual obstruction is present.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Cardiovascular Medicine

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) presents a challenge in managing left ventricular outflow tract (LVOT) obstruction.
  • Patients with basal septal thickness <18 mm are often deemed unsuitable for myectomy, leading to mitral valve replacement.
  • Evaluating the impact of septal thickness on myectomy outcomes is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To determine if basal septal thickness influences the outcomes and adequacy of transaortic septal myectomy in HOCM patients.
  • To assess the necessity of concomitant mitral valve procedures based on septal thickness.

Main Methods:

  • Retrospective review of 1486 adult HOCM patients undergoing transaortic septal myectomy (2005-2014).
  • Patients were grouped by basal septal thickness: <18 mm, 18-21 mm, and >21 mm.
  • Statistical analysis included Kruskal-Wallis, Pearson chi-squared tests, and ANCOVA.

Main Results:

  • All groups achieved significant postoperative gradient relief (median reduction: 51-54 mmHg).
  • Concomitant mitral valve procedures were performed in a similar proportion across groups (7.6-8.1%).
  • Ventricular septal defect occurred rarely (0.3%) with no significant difference between groups.

Conclusions:

  • Transaortic septal myectomy provides adequate LVOT obstruction relief for HOCM patients with basal septal thickness <18 mm.
  • Mitral valve intervention should be reserved for intrinsic mitral valve disease or persistent obstruction post-myectomy.
  • Septal thickness alone should not preclude septal myectomy as an effective treatment option.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
381
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
539
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
489
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
611
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
800
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K